NCT05641896 - Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers | Biotech Hunter

Enrollment

109

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

July 1, 2025

Study Completion Date

July 1, 2025

Conditions

Gastrointestinal CancersCholangiocarcinomaGastric CancerColorectal CancerPancreatic Ductal AdenocarcinomaHepatocellular Carcinoma

Interventions

DRUG

[18F]FAPI-74 PET/CT

\[18F\]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with gastrointestinal cancers.

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center (MSKCC), New York

11042

Northwell Health, Lake Success

49503

BAMF Health, Grand Rapids

55902

Mayo Clinic Rochester, Rochester

90095

University of California Los Angeles (UCLA) Health, Los Angeles

02114

Massachusetts general hospital, Boston